<DOC>
	<DOC>NCT01211002</DOC>
	<brief_summary>It is a trials to evaluate the overall survival (OS) of radiotherapy / EP combined with recombinant human endostatin in treatment of locally advanced (Ⅲ A / unresectable Ⅲ B) non-small cell lung cancer.</brief_summary>
	<brief_title>Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin for Local Advanced Non-small Cell Lung Cancer (NSCLC)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<criteria>1. Patients with pathologically or histologically confirmed and inoperable stage Ⅲ (Ⅲ A or unresectable Ⅲ B) NSCLC; 2. Patients with ages of 18~70 years, general condition ECOG performance scale （PS）≤ 1, weight loss &lt;10% during last 6 months; 3. CT films of patients during last 4 weeks were accessible when patients were selected into the groups, the lesions were measurable; (According to the standard of RECIST1.1, they should have at least one of accurately measurable lesions with the largest diameter ≥ 10mm by spiral CT, PETCT, with the largest diameter≥ 20mm by ordinary CT and MRI.） 4. No major organ dysfunction, the function of heart, liver and kidney was normal, laboratory indicators should meet the following requirements: Blood: WBC&gt; 4.0 × 109 / L, absolute neutrophil count &gt; 1.5 × 109 / L, platelet count&gt; 100 × 109 / L, hemoglobin&gt; 110g / L; liver function: serum bilirubin was less than 1.5 × maximum normal value ; ALT and AST were less than 1.5 × maximum normal value; BUN, Cr within the normal range; FEV1 &gt; 1L or&gt; 40% of predicted value; 5. Patients could understand the circumstances of this study and those who have signed the informed consent form; 1. Pregnant or lactating women; women of childbearing age without contraception; 2. Acute infection or other serious underlying diseases; 3. Significant neurological, psychiatric history, including dementia which may influence the ability to understand and the informed consent; 4. Receive the treatment of other experimental trials in the same period; on the medication of other anticancer drugs a the same time; have joined other drug clinical trials 30 days before this clinical trial; 5. Diabetes without control (bloodglucose is unstable or ≥ 8mol / L after administration); 6. Patients who are allergic to E. coli preparation; 7. Patients who are unsuitable to participate in this trial determined by the researchers.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Radiotherapy</keyword>
	<keyword>rh-endostatin</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>NSCLC</keyword>
</DOC>